Efficacy and safety of switching basal insulin to insulin glargine 300 U/ <scp>mL</scp> in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo <scp>T2DM</scp> study

Switching BI to Gla-300 from a BOTplus or MDI regimen with prior insulin Gla-100, IDeg, IDet, or NPH improved glycaemic control in participants with inadequately controlled T2DM over 12 months without increasing hypoglycaemia risk or weight gain.